Top

International Journal of Colorectal Disease

Published in:

01-01-2010 | Original Article

Downregulation of IGF-IR expression by RNAi inhibits proliferation and enhances chemosensitization of human colon cancer cells

Authors: Kamal Yavari, Mohammad Taghikhani, Mohammad Ghannadi Maragheh, Seyed A. Mesbah-Namin, Mohammad Hossein Babaei

Published in: International Journal of Colorectal Disease | Issue 1/2010

Abstract

Purpose

Colon cancer is the second leading cause of cancer death worldwide. Elevated expression of insulin-like growth factor-I receptor (IGF-IR) is a frequent genetic abnormality seen in this malignancy. For a better understanding of its role in maintaining the malignant phenotype, we used RNA interference (RNAi) directed against IGF-IR in our study. The aim of this study was to examine the anti-proliferation and chemosensitization effects elicited by a decrease in the transcription and protein levels of IGF-IR by RNAi in SW480 colon cancer cells.

Methods

A plasmid-based polymerase III promoter system was used to deliver and express short interfering RNA (siRNA) targeting IGF-IR to reduce its expression in SW480 cells. Western blot analysis was used to measure the protein level of IGF-IR. We assessed the effects of IGF-IR silencing on cancer cell growth by a cell growth curve. The effect of the 5-fluorouracil (5-FU)-induced cell death by knockdown of IGF-IR was also investigated by methyl thiazolyl tetrazolium assay.

Results

Transfection of siRNA targeting IGF-IR was shown to reduce IGF-IR messenger RNA levels by 95%. Western blotting detected a similar inhibition of IGF-IR protein levels in those cells. The cells transfected with PKD-short hairpin RNA-IGF-IR-V2 significantly decreased cell growth and rendered cells more sensitive to chemotherapy. The highest proliferation inhibitory and chemosensitization ratios were 53 ± 2% and 1.78, respectively.

Conclusion

This study indicates that downregulation of IGF-IR results in significant inhibition of tumor growth in vitro. It also provides a promising strategy to chemotherapy efficacy in human tumors and forming a basis for future in vivo trials.

Cohen SJ, Cohen RB, Meropol NJ (2005) Targeting signal transduction pathways in colorectal cancer—more than skin deep. J Clin Oncol 23:5374–5385CrossRefPubMed

Waters C (2006) Colorectal cancer: an overview. Pharm J 27:323–326CrossRef

Labianca R, Beretta G, Gatta G, de Braud F, Wils J (2004) Colon cancer. Crit Rev Oncol Hematol 51:145–170CrossRefPubMed

Ansari R, Mahdavinia M, Sadjadi A et al (2006) Incidence and age distribution of colorectal cancer in Iran. Results of a population-based cancer registry. Cancer Lett 240:143–147CrossRefPubMed

Grady WM (2005) Epigenetic events in the colorectum and in colon cancer. Biochem Soc Trans 33:684–686CrossRefPubMed

Williams NS, Gaynor RB, Scoggin S et al (2003) Identification and validation of genes involved in the pathogenesis of colorectal cancer using cDNA microarrays. Clin Cancer Res 9:931–946PubMed

LeRoith D, Roberts CT Jr (2003) The insulin-like growth factor system and cancer. Cancer Lett 195:127–137PubMed

Yu H, Rohan T (2000) Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 92:1472–1489CrossRefPubMed

Shoshana Y, Pnina LB (2005) The role of the growth hormone/insulin-like growth factor axis in tumor growth and progression: lessons from animal models. Cytokine Growth Factor Rev 16:407–420CrossRef

10.

Baker J, Liu JP, Robertson EJ, Efstratiadis A (1993) Role of insulin like growth factors in embryonic and postnatal growth. Cell 75:73–82PubMed

11.

Rosen CJ, Pollak M (1999) Circulating IGF-I: new perspectives for a new century. Trends Endocrinol Metab 10:136–141CrossRefPubMed

12.

Guerreiro AS, Boller D, Doepfner KT, Arcaro A (2006) IGF-IR: potential role in antitumor agents. Drug News Perspect 19:261–272CrossRefPubMed

13.

Sepp-Lorenzino L (1998) Structure and function of the insulin-like growth factor I receptor. Breast Cancer Res Treat 47:235–253CrossRefPubMed

14.

De Meyts P, Whittaker J (2002) Structural biology of insulin and IGF1 receptors: implications for drug design. Nat Rev Drug Discov 1:769–783CrossRefPubMed

15.

Samani AA, Yakar S, LeRoith D, Brodt P (2006) The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev 28:20–47CrossRefPubMed

16.

Valentinis B, Baserga R (2001) IGF-I receptor signalling in transformation and differentiation. Clin Mol Pathol 54:133–137CrossRef

17.

Favelyukis S, Till JH, Hubbard SR, Miller WT (2001) Structure and autoregulation of the insulin like growth factor I receptors. Nat Struct Biol 8:1058–1063CrossRefPubMed

18.

Monzavi R (2002) IGFs and IGFBPs roles in health and disease. Best Pract Res Clin Endocrinol Metab 16:437–447CrossRef

19.

Stewart CE, Rotwein P (1996) Growth, differentiation, and survival: multiple physiological functions for insulin-like growth factors. Physiol Rev 76:1005–1026PubMed

20.

Weber MM, Fottner C, Liu SB et al (2002) Overexpression of the insulin-like growth factor I receptor in human colon carcinomas. Cancer 95:2086–2095CrossRefPubMed

21.

Corinna B, Bernd G (2004) The insulin like growth factor-1 receptor (IGF-1R) as a drug target: novel approaches to cancer therapy. Growth Horm IGF Res 14:287–295CrossRef

22.

Burtrum D, Zhu Z, Lu D et al (2003) A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. Cancer Res 63:8912–8921PubMed

23.

Sachdev D, Hartell JS, Lee AV (2004) A dominant negative type I insulin-like growth factor receptor inhibits metastasis of human cancer cells. J Biol Chem 279:5017–5024CrossRefPubMed

24.

Chernicky CL, Tan L, Gan SU, Ilan J (2000) Treatment of human breast cancer cells with antisense RNA to the type I insulin-like growth factor receptor inhibits cell growth, suppresses tumorigenesis, alters the metastatic potential, and prolongs survival in vivo. Cancer Gene Ther 7:384–395CrossRefPubMed

25.

Gudkov AV, Zelnick CR, Kazarov AR et al (1993) Isolation of genetic suppressor elements, inducing resistance to topoisomerase II—interactive cytotoxic drugs, from human topoisomerase II cDNA. Proc Natl Acad Sci U S A 90:3231–3235CrossRefPubMed

26.

Collins FS, Green ED, Guttmacher AE, Guyer MS (2002) A vision for the future of genomic research. Nature 422:835–847CrossRef

27.

Grünweller A, Wyszko E, Bieber B, Jahnel R, Erdmann VA, Kurreck J (2003) Comparison of different antisense strategies in mammalian cells using locked nucleic acids, 2′-O-methyl RNA, phosphorothioates and small interfering RNA. Nucleic Acids Res 31(12):3185–3193CrossRefPubMed

28.

Scherer LJ, Rossi JJ (2003) Approaches for the sequence-specific knockdown of mRNA. Nat Biotechnol 21:1457–1465CrossRefPubMed

29.

Milhavet O, Gary DS, Mattson MP (2003) RNA Interference in biology and medicine. Pharmacol Rev 55:629–648CrossRefPubMed

30.

Pfeffer S, Meister G, Landthaler M, Tuschl T (2005) RNA silencing. BIF Futura 20:83–90

31.

Downward J (2004) RNA interference. Br Med J 328:1245–1248CrossRef

32.

Sumimoto H (2005) Use of RNA interference technology for specific gene silencing. Ann Cancer Res Ther 13:23–25

33.

Dykxhoorn DM, Novina CD, Sharp PA (2003) Killing the messenger: short RNAs that silence gene expression. Nat Rev Mol Cell Biol 4:457–467CrossRefPubMed

34.

Barik S (2005) Silence of the transcripts: RNA interference in medicine. J Mol Med 83:764–773CrossRefPubMed

35.

Friedrich I, Shir A, Klein S, Levitzki A (2004) RNA molecules as anti-cancer agents. Semin Cancer Biol 14:223–230CrossRefPubMed

36.

Masiero M, Nardo G, Indraccolo S, Favaro E (2007) RNA interference: implication for cancer treatment. Mol Aspects Med 28:143–166CrossRefPubMed

37.

Chung-Faye GA, Kerr DJ (2000) Innovative treatment for colon cancer. Br Med J 321(2):1397–1399CrossRef

38.

LeRoith D, Werner H, Beitner JD, Roberts CT (1995) Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr Rev 16:143–163PubMed

39.

Uprichard SL (2005) The therapeutic potential of RNA interference. FEBS Lett 579:5996–6007CrossRefPubMed

40.

Bantounas I, Phylactou LA, Uney JB (2004) RNA interference and the use of small interfering RNA to study gene function in mammalian systems. J Mol Endocrinol 33:545–557CrossRefPubMed

41.

Nagy P, Arndt-Jovin DJ, Jovin TM (2003) Small interferencing RNAs suppress the expression of endogenous and GFP-fused epidermal growth factor receptor and induce apoptosis in erbB1-overexpressing cells. Exp Cell Res 285:39–49CrossRefPubMed

42.

Sui G, Soohoo C, Affarel BB et al (2002) A DNA vector-based RNAi technology to suppress gene expression in mammalian cells. Proc Natl Acad Sci U S A 99:5515CrossRefPubMed

43.

Mittal V (2004) Improving the efficiency of RNA interference in mammals. Nature 5:355–365

44.

Tuschl T (2002) Expanding small RNA interference. Nat Biotechnol 20:500–505CrossRef

45.

Kaykas A, Moon RT (2004) A plasmid-based system for expressing small interfering RNA libraries in mammalian cells. BMC Cell Biol 5:1–11CrossRef

46.

Brummelkamp TR, Bernards R, Agami R (2002) A system for stable expression of short interfering RNAs in mammalian cells. Science 296:550–553CrossRefPubMed

Title: Downregulation of IGF-IR expression by RNAi inhibits proliferation and enhances chemosensitization of human colon cancer cells
Authors: Kamal Yavari
Mohammad Taghikhani
Mohammad Ghannadi Maragheh
Seyed A. Mesbah-Namin
Mohammad Hossein Babaei
Publication date: 01-01-2010
Publisher: Springer-Verlag
Published in: International Journal of Colorectal Disease / Issue 1/2010
Print ISSN: 0179-1958
Electronic ISSN: 1432-1262
DOI: https://doi.org/10.1007/s00384-009-0783-2

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Downregulation of IGF-IR expression by RNAi inhibits proliferation and enhances chemosensitization of human colon cancer cells

Abstract

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2010

Pilot study of bipolar radiofrequency-induced anastomotic thermofusion–exploration of therapy parameters ex vivo

Rectal endosonography: just how good are we at its interpretation?

Stent or surgery for incurable obstructive colorectal cancer: an individualized decisión

An updating meta-analysis of the glutathione S-transferase T1 polymorphisms and colorectal cancer risk: a HuGE review

Prediction of histology and invasive depth of colorectal neoplasia based on morphology of surface depression using magnifying chromocolonoscopy

CTLA-4 +49A>G polymorphism is associated with the risk but not with the progression of colorectal cancer in Chinese